My Cart [ 0 ]
Home > Chemicals > Inhibitors, Activators, Antagonists, and Agonists > A-Z Inhibitors, Activators, Antagonists, and Agonists > AZD4635 (HTL-1071)

AZD4635 (HTL-1071)

HTL-1071

Catalog No. Product Name Size List Price (US$) Quantity
APIM050269 AZD4635 (HTL-1071) 10 mg 135.00
APIM050269 AZD4635 (HTL-1071) 50mg 250.00
APIM050269 AZD4635 (HTL-1071) 100 mg 400.00
APIM050269 AZD4635 (HTL-1071) 200 mg 700.00
Description

Background Information:

AZD4635 (HTL-1071) is an orally bioavailable, potent and selective A2A (Adenosine 2A) receptor antagonist, binding to human A2A receptor with a Ki value of 1.7 nM, and with > 30-fold selectivity over other adenosine receptors. High adenosine level in tumors, produced by stimulating A2A receptors, is immune suppressive, which prevents T-cells within the immune system from being activated thus reduces their ability to destroy cancer cells. Antagonizing A2A receptors can therefore promote the anti-cancer response of T-cells within the tumour microenvironment. AZD4635 is currently being evaluated as a monotherapy and in combination with other anti-PDL1 agents in patients with advanced solid cancers.

APIM050269: AZD4635 (HTL-1071)

CAS No.: 1321514-06-0.
Molecular Formula: C15H11ClFN5.
Molecular Weight: 315.7.
Purity: >99% by HPLC.
QC: HPLC-MS, 1H-NMR, and Quantitative Elemental Analysis.
Solubility: Refer to Certificate of Analysis.
Storage: Refer to Certificate of Analysis.

Related Links

See our Privacy Policy